Cargando…

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia

Acquired drug resistance in childhood T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clinical problem. In this study, a novel gene therapy target for childhood T-ALL to overcome chemoresistance was discovered: TFDP3 increased in the minimal residual disease (MRD) positive childhoo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Ming, Yin, Kailin, Dong, Yujun, Wang, Pingzhang, Xue, Yun, Zhou, Peng, Wang, Yuqi, Wang, Yuedan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352064/ https://www.ncbi.nlm.nih.gov/pubmed/27902457 http://dx.doi.org/10.18632/oncotarget.13630

Ejemplares similares

TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer
por: Yin, Kailin, et al.
Publicado: (2017)

TFDP3 as E2F Unique Partner, Has Crucial Roles in Cancer Cells and Testis
por: Huang, Jiahao, et al.
Publicado: (2021)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

Minimal residual disease in childhood B Lymphoblastic Leukemia and its correlation with other risk factors
por: Meraj, Fatima, et al.
Publicado: (2020)

Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide
por: Ede, Benjamin C., et al.
Publicado: (2018)

Effects of cancer-testis antigen, TFDP3, on cell cycle regulation and its mechanism in L-02 and HepG2 cell lines in vitro
por: Jiao, Yunshen, et al.
Publicado: (2017)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Measurable residual disease in childhood B-cell acute lymphoblastic leukemia
por: Gale, Robert Peter
Publicado: (2022)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

TFDP3 regulates the apoptosis and autophagy in breast cancer cell line MDA-MB-231
por: Ding, Ling-yu, et al.
Publicado: (2018)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia using TEL‐AML1 fusion transcript as a marker
por: Zhao, Xiaoxi, et al.
Publicado: (2019)

Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia
por: Schraw, Jeremy M., et al.
Publicado: (2019)

NET1 Enhances Proliferation and Chemoresistance in Acute Lymphoblastic Leukemia Cells
por: Sun, Hongbo, et al.
Publicado: (2019)

The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia
por: Meyer, Lauren K., et al.
Publicado: (2019)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Inherited GATA3 variant associated with positive minimal residual disease in childhood B‐cell acute lymphoblastic leukemia via asparaginase resistance
por: Li, Chunjie, et al.
Publicado: (2021)

Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction
por: Cheng, Suk Hang, et al.
Publicado: (2013)

Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia
por: Wang, Yu, et al.
Publicado: (2021)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
por: Besbes, S., et al.
Publicado: (2017)

The Microbiome in Childhood Acute Lymphoblastic Leukemia
por: Oldenburg, Marina, et al.
Publicado: (2021)

Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing
por: Wu, Jinghua, et al.
Publicado: (2016)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
por: Gidman, Wendy, et al.
Publicado: (2019)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia
por: Ariës, Ingrid M., et al.
Publicado: (2018)

An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes
por: Fan, Zhiwen, et al.
Publicado: (2021)

Obesity in patients with acute lymphoblastic leukemia in childhood
por: Iughetti, Lorenzo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k4huafndbikfdjnqmp94eq8hj3